Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
ETNK1 mutations in atypical chronic myeloid leukaemia can be reverted with phosp...
Dr Diletta Fontana - The University of Milano-Bicocca, Milan, Italy
ETNK1 mutations in atypical chronic myeloid leukaemia can be reverted with phosphoethanolamine ( Dr Diletta Fontana - The University of Milano-Bicocca, Milan, Italy )
11 Dec 2020
Latest data for managing ALK NSCLC patients
Prof Myung-Ju Ahn - Samsung Medical Center, Seoul, South Korea
Latest data for managing ALK  NSCLC patients ( Prof Myung-Ju Ahn - Samsung Medical Center, Seoul, South Korea )
11 Dec 2020
FORTE: Impact of imaging FDG-PET/CT minimal residual disease assessment on multi...
Dr Elena Zamagni - University of Bologna, Bologna, Italy
FORTE: Impact of imaging FDG-PET/CT minimal residual disease assessment on multiple myeloma patients ( Dr Elena Zamagni - University of Bologna, Bologna, Italy )
10 Dec 2020
Clinical activity and safety of cevostamab in relapsed/refractory multiple myelo...
Prof Adam Cohen - University of Pennsylvania, Philadelphia, USA
Clinical activity and safety of cevostamab in relapsed/refractory multiple myeloma ( Prof Adam Cohen - University of Pennsylvania, Philadelphia, USA )
10 Dec 2020
Pregnancy outcomes in breast cancer survivors; meta-analysis
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
Pregnancy outcomes in breast cancer survivors; meta-analysis ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
10 Dec 2020
ASCEMBL: Asciminib for hard-to-treat chronic myeloid leukaemia
Prof Andreas Hochhaus - Universitätsklinikum Jena, Jena, Germany
ASCEMBL: Asciminib for hard-to-treat chronic myeloid leukaemia ( Prof Andreas Hochhaus - Universitätsklinikum Jena, Jena, Germany )
10 Dec 2020
ASCENT: A phase II trial of induction, consolidation and maintenance in subjects...
Prof Andrzej Jakubowiak - University of Chicago, Chicago, USA
ASCENT: A phase II trial of induction, consolidation and maintenance in subjects with high risk smouldering MM ( Prof Andrzej Jakubowiak - University of Chicago, Chicago, USA )
9 Dec 2020
Inotuzumab ozogamicin in paediatric CD22-positive r/r acute lymphoblastic leukae...
Dr Erica Brivio - Princess Máxima Center for Pediatric Oncology, Utrecht, Nether...
Inotuzumab ozogamicin in paediatric CD22-positive r/r acute lymphoblastic leukaemia: results of the ITCC-059 study ( Dr Erica Brivio - Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands )
9 Dec 2020
MURANO: Sustained disease survival in CLL following venetoclax plus rituximab
Dr Arnon Kater - Cancer Center Amsterdam, Amsterdam, Netherlands
MURANO: Sustained disease survival in CLL following venetoclax plus rituximab ( Dr Arnon Kater - Cancer Center Amsterdam, Amsterdam, Netherlands )
9 Dec 2020
Comparing outcomes of first-line ibrutinib vs chemoimmunotherapy in high-risk CL...
Dr Lori Leslie - John Theurer Cancer Center, Hackensack, USA
Comparing outcomes of first-line ibrutinib vs chemoimmunotherapy in high-risk CLL ( Dr Lori Leslie - John Theurer Cancer Center, Hackensack, USA )
9 Dec 2020
OncoAlert and ecancer weekly roundup for November 22 - Dec 5, 2020
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly roundup for November 22 - Dec 5, 2020 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
9 Dec 2020
Novel bispecific T-cell engager molecule shows promise in r/r multiple myeloma
Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia
Novel bispecific T-cell engager molecule shows promise in r/r multiple myeloma ( Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia )
9 Dec 2020